Literature DB >> 15770098

Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.

Cheol-In Kang1, Sung-Han Kim, Wan Beom Park, Ki-Deok Lee, Hong-Bin Kim, Eui-Chong Kim, Myoung-Don Oh, Kang-Won Choe.   

Abstract

This study was conducted to evaluate risk factors for antimicrobial resistance and influence of resistance on mortality in Pseudomonas aeruginosa bacteremia. Data on 190 patients with P. aeruginosa bacteremia were analyzed retrospectively. Antimicrobial resistance to antipseudomonal antibiotics was evaluated. The main outcome measure was 30-day mortality. In P. aeruginosa bacteremia, resistance rates to piperacillin (PIP), ceftazidime (CAZ), ciprofloxacin (CIP), and imipenem (IPM) were 29 (56/190), 19 (36/190), 17 (32/190) and 15% (28/190), respectively. Prior uses of fluoroquinolones or carbapenems were independent risk factors for resistance to CIP and IPM, and prior use of extended-spectrum cephalosporins was a risk factor for PIP-R. An indwelling urinary catheter was a risk factor for PIP-R, CAZ-R, and CIP-R. An invasive procedure was a risk factor for CIP-R and IPM-R. The 30-day mortality rate was 44% (33/75) in patients infected by strains resistant to any of the antipseudomonal antibiotics, but 33.9% (39/115) in those by strains susceptible to all antipseudomonal antibiotics (p = 0.161). Among patients with bloodstream infection due to antimicrobial-resistant P. aeruginosa, those infected by IPM-R strains had the highest mortality (IPM-R, 53.6% vs. CAZ-R, 47.2% vs. CIP-R 46.9%, PIP-R, 39.3%). In this study regarding P. aeruginosa bacteremia, prior uses of fluoroquinolones, carbapenems, or extended-spectrum cephalosporins, a prior invasive procedure, and an indwelling urinary catheter were found to be associated with antimicrobial resistance. The patients with bloodstream infection caused by antimicrobial-resistant P. aeruginosa, especially to imipenem, had a tendency toward higher mortality than those infected by susceptible strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770098     DOI: 10.1089/mdr.2005.11.68

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  27 in total

1.  Role of hospital stay and antibiotic use on Pseudomonas aeruginosa gastrointestinal colonization in hospitalized patients.

Authors:  D Lepelletier; N Caroff; D Riochet; P Bizouarn; A Bourdeau; F Le Gallou; E Espaze; A Reynaud; H Richet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

Review 2.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

3.  Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa.

Authors:  Nimish Patel; Louise-Anne McNutt; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

4.  Multiple-Drug Resistance in Burn Patients: A Retrospective Study on the Impact of Antibiotic Resistance on Survival and Length of Stay.

Authors:  Ilse van Langeveld; Robin C Gagnon; Peggie F Conrad; Richard L Gamelli; Brendan Martin; Mashkoor A Choudhry; Michael J Mosier
Journal:  J Burn Care Res       Date:  2017 Mar/Apr       Impact factor: 1.845

5.  Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia.

Authors:  Regina B Osih; Jessina C McGregor; Shayna E Rich; Anita C Moore; Jon P Furuno; Eli N Perencevich; Anthony D Harris
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

6.  Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.

Authors:  Chi Hyun Kim; Hee Young Kang; Bo Ra Kim; Hyejin Jeon; Yoo Chul Lee; Sang Hwa Lee; Je Chul Lee
Journal:  J Microbiol       Date:  2016-01-05       Impact factor: 3.422

7.  Detection of metallo-beta-lactamase producing Pseudomonas aeruginosa in intensive care units.

Authors:  Arunava Kali; Sreenivasan Srirangaraj; Shailesh Kumar; Hema A Divya; Akhila Kalyani; Sivaraman Umadevi
Journal:  Australas Med J       Date:  2013-12-31

8.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 9.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.

Authors:  Mario Tumbarello; Gennaro De Pascale; Enrico Maria Trecarichi; Teresa Spanu; Federica Antonicelli; Riccardo Maviglia; Mariano Alberto Pennisi; Giuseppe Bello; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2013-02-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.